Oligonucleotide Synthesis Market Research Report: By Product (Oligonucleotide, Reagents and Equipment), By Type (Custom Oligos and Predesigned Oligos), By Application (Therapeutic Applications, Diagnostics, Research and others), By End User (Academic Research Institutes, Pharmaceutical and Biotechnology Companies, Diagnostic Laboratories and others) - Forecast till 2027
ID: MRFR/LS/1721-HCR | February 2021 | Region: Global | 95 pages
Oligonucleotide Synthesis Market Overview
The oligonucleotide synthesis market size is projected to grow by 7.2% in the forecast period. The oligonucleotide is a chemical synthesis that contains short fragments of nucleic acids. This oligonucleotide synthesis procedure is beneficial for laboratories as creating custom made oligonucleotide are possible. Today, the rate of diseases is sharply increasing in many regions. However, molecular diagnosis for infectious disease is achievable through oligonucleotide. Hepatitis and cancer are chronic illnesses that require effective medicines. For these diseases, the oligonucleotide is a suitable component.
There are several benefits of this component in the medical world. Also, the clinical applications of this compound are a wide range that is for the detection of autoimmune antibodies. The rise of research in genome sequencing is providing more scope for the oligonucleotide. The growth of biotechnical companies is massive. The development of vaccines and medicines is raising the demand for such companies. Due to its growth oligonucleotide has a positive impact.
More utilizations of oligonucleotide synthesis in labs are expected to create more awareness for this component. The investments for oligonucleotide synthesis are rising every year. Its efficient application to detect antibodies and treat cancer is the surging use of the oligonucleotide. In the upcoming years, the oligonucleotide synthesis market is estimated to have tremendous developments. All these factors will ultimately raise oligonucleotide synthesis market value.
Covid analysis
The covid 19 virus is affecting millions of individuals. Since the outbreak of the virus economic crisis is affecting various industries. During this period, the health industry has massive demand. It is causing a health burden on various health facilities. Biopharmaceutical companies and oligonucleotide firms are helping the health industry in the period. These companies are providing necessary health kits, medications and vaccines for the patients. It is taking the oligonucleotide synthesis market a step forward. Research in the oligonucleotide industry is immense.
The oligonucleotide labs are researching to check the potential of this component in vaccines. Also, new partnerships and establishments are bringing more developments to the oligonucleotide synthesis market. The oligonucleotide primers and wide range of products have exceptional demand. There few factors that decline the market demand. The supply chain disruptions are decreasing the availability of oligonucleotide products. However, post covid 19 scenario is highly positive.
Market dynamics
- Crucial market drivers
The surging government investments for synthesis biology are a crucial market driver. Governmental support helps in technological advancements on the market. The funding and investment by the oligos are beneficial for the high demand of the oligonucleotide synthesis market. Further, the high usage of pharmaceutical companies is a driving factor of the market.
In recent years, biopharmaceutical companies are collecting more than 10000 genetic samples. It is to conduct various clinical trials for the oligonucleotide market. Through this process, treating complex diseases is possible. Including these oligonucleotide components in drugs and medication is raising the demand. All these factors will boost the overall adoption rate.
Further, the expansion of the health sector is another factor driving demand. This advancement is leading to high demand for oligonucleotide synthesis. The new hospitals and health facilities are investing in this component for better treatment of the patients. Additionally, the demand from the developed region is another crucial driver for the oligonucleotide synthesis market. The developed regions such as North America have higher awareness for oligonucleotide synthesis. Better and efficient utilization of this component in gene sequencing is leading to high demand. All these factors of the market will increase the adoption rate of RNA oligonucleotide synthesis.
- The market growth opportunities
Demand from emerging economies will bring growth opportunities for the oligonucleotide synthesis market. In recent years, demand from China, India, Japan and Singapore markets is high. This expansion of the market is opening new opportunities for the oligonucleotide synthesis market. China is opening a new facility for RNA oligonucleotide synthesis procedures. To meet the current demand these facilities are helpful. The portfolio and leading oligonucleotide synthesis product will increase revenue rates.
Further, new approvals for oligonucleotide synthesis drugs are happening in the Asia Pacific region. Especially, spinal muscular diseases are effectively treatable through this component. The approval of new medical products in this region increases the supply rates.
Further, Japan is opening a new facility for research of oligonucleotide synthesis. These labs will develop oligonucleotide synthesis technologies. It is another factor that will turn consumer attention towards the oligonucleotide synthesis market. Governmental support in Singapore is enabling the growth of pharma companies. New establishments and collaborations are rapidly taking place. Altogether, these factors will lead to impeccable opportunities for the oligonucleotide synthesis market. The development of biosynthesis in this region is high.
- The market restraint
The issues with therapeutic oligonucleotide synthesis are a market restraint. Awareness of synthetic oligos is high in recent years. The main target of this component is to identify the human genome. These therapeutic oligos are useful to treat infections, cancer, viral disease and rare disease. It is an effective treatment for rare thrombotic and fibrosis.
However, the side effects of these drugs are increasing. Many of these treatments do not pass the clinical trials. The failure rates of solid phase oligonucleotide synthesis drugs are high. For every clinical trial, the market puts in massive capital. These failures and side effects can affect oligonucleotide synthesis market growth. Also, the revenue rates of the market are restricted. Long term side effects are major factors that decline demand.
- The market challenges
The poor delivery systems supply oligonucleotide synthesis drugs. The application of gene therapy is ruing tumour cells. In both clinical and experimental forms, these drugs are effective. However, the poor channel to supply these drugs is a significant challenge. Supplying these to the target customer is inefficient.
The poor delivery channels are a major cause of this channel. The market needs the development of delivery vendors. Also, it will ensure the safe and secure delivery of oligonucleotide synthesis drugs. Further, the fewer technologies to engage therapeutic drugs are another challenge. These challenges can hamper oligonucleotide synthesis market growth.
- Cumulative growth analysis
The oligonucleotide synthesis market report shows a surging growth trend. The factors that lead to high growth are governmental investments and health industry expansion. These factors expand and develop the oligonucleotide synthesis market. The antisense oligonucleotide market is drug-based.
It is a profitable segment of the market. The demand for these drugs is immense in emerging economies. Further, the adoption rate of this component is highest in hospitals. However, the barriers of the market are side effects and poor delivery channels. These challenges are expected to impede growth. Still, the overall growth rate is substantial with vast opportunities in emerging economies.
- Value chain analysis
North America is accounted for maximum market shares. The importance of life science is high in North America. Improving health care application is leading to the effective use of oligonucleotide synthesis. The tools to produce drugs are high end in oligonucleotide synthesis market. Also, investments in the health industry are in millions.
The personalized therapeutic is bring great opportunities. Top leaders in the market take care of all the market operations well. The profitable key players make new developments and product launches. Also, there are only fewer barriers in North America. It leads to high growth in regions such as US and Canada.
Segment overview
By product
- Primers
- RNA Oligos
- Other Synthesized Oligos
- Probes
- DNA Oligos
By type
- Predesigned oligos
- Customize oligos
- Equipment
- Reagent
By application
- Research application
- Sequencing
- PCR
- Diagnostic application
By type
- CpG oligonucleotide synthesis therapy
- Antisense oligonucleotide synthesis
- RNA oligonucleotide synthesis
By disease type
- Infectious disease
- Neurological disorders
By end-user
- Academic research
- Hospitals
- Pharmaceuticals
- Diagnostic laboratory
By region
- Asia pacific
- Europe
- North America
- Middle East Africa
- Latin America
Competitive landscape
The competition in the oligonucleotide synthesis market is expected to increase. Various market acquisitions will happen in the market. Expanding product portfolio is a key strategy of key players.
Regional analysis
The regional segment of the oligonucleotide synthesis market has three major players. Asia Pacific, Europe and North America contribute the highest for the oligonucleotide synthesis market. North America will dominate the oligonucleotide synthesis in the forecast period. Also, the developed health infrastructure is the major cause of high demand. Effective use of oligonucleotide synthesis to cure chronic illness will enhance the growth rate.
Further, Asia Pacific is the next largest market with rapid growth. Developing an economy and government support are two factors that stir demand. “Genome India project” will create massive scope in Asia pacific. The oligonucleotide synthesis market collects thousands of genetic samples for clinical trials. All these will bring high growth prospects in the regional market.
The key players of the oligonucleotide synthesis market are
- Thermo Fisher Scientific Inc.
- Adtbio, Merck - Co. Inc.
- Bio-Synthesis Inc.
- Eurofins Genomics
- GE Healthcare
- Horizon Discovery Ltd
- Agilent Technologies
- Genscript
- Kaneka Eurogentec SA
- Nitto Denko Avecia
- Integrated DNA Technologies Inc.
- BioAutomation
- LGC Biosearch Technologies
- Sarepta therapeutics
- Agilent Technologies
Recent developments
- The Danaher Corporation is opening a new business entity in China. It will meet the high demand from the customer base. This new development will help to reach out wider opportunities in china.
- The LGC groups partnered with the molecular biology Company to create new tests. The custom quality molecular products and tests will happen.
- Thermo Fisher is making a new agreement with the molecular production company. It will receive raw materials from the company.
Market overview
- Market overview highlights
- Analysis based upon COVID 19
- Explanation upon the Market Dynamics
- Value chain analysis
- Market segmentation overview
- The regional analysis
- Competitive landscape analysis
- Recent Developments
Report Scope:
| Report Attribute/Metric | Details |
|---|---|
| Market Size | 2027: Significant Value |
| CAGR | 7.2% (2020-2027) |
| Base Year | 2019 |
| Forecast Period | 2027 |
| Historical Data | 2018 |
| Forecast Units | Value (USD Million) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Segments Covered | Product, Type, Application, End User |
| Geographies Covered | North America, Europe, Asia-Pacific, and Rest of the World (RoW) |
| Key Vendors | Thermo Fisher Scientific, Inc., Adtbio, Merck - Co., Inc., Bio-Synthesis Inc., Eurofins Genomics, GE Healthcare, Horizon Discovery Ltd, Agilent Technologies, Genscript, Kaneka Eurogentec SA, Nitto Denko Avecia, Integrated DNA Technologies, Inc., BioAutomation, LGC Biosearch Technologies, Sarepta therapeutics, Agilent Technologies |
| Key Market Opportunities | The Existence of Better health care infrastructure and increasing usage of oligonucleotides by pharmaceutical companies of the region and many strategic collaborations among the players in the market. |
| Key Market Drivers | New product launches and R&D Amongst major key Players |
Frequently Asked Questions (FAQ) :
Oligonucleotide Synthesis Market is projected grow at approximately 13.19% CAGR during the assessment period (2019-2025).
Technological advancements, rising disposable income levels of patients, huge investments from big pharmaceutical companies in oligonucleotide synthesis for drug development, CMO’s involvement in manufacturing therapeutic oligonucleotides, and wide application areas offered by the oligonucleotides.
North America holds the largest share in the Global Oligonucleotide Synthesis Market, followed by Europe and the Asia Pacific, respectively.
GE Healthcare (U.S.), Integrated DNA Technologies, Inc. (U.S), Agilent Technologies Inc. (U.S.), Bioautomation Corporation (U.S.), Sigma-Aldrich Corporation (U.S.), Thermo Fisher Scientific Inc. (U.S.), Eurofins Genomics (Germany), L.G.C Biosearch Technologies (U.S.), Nitto Denko Avecia Inc. (Japan), and Eurogentec S.A (Belgium), are some of the major players operating in the oligonucleotide synthesis market.
Strategic initiatives such as mergers & acquisitions, collaborations, expansion, and technology/ product launch are some of the growth strategies that players operating in the global oligonucleotide synthesis market adopt to gain a larger competitive advantage.